Tuesday, 3 December 2013

Hepatitis C Virus - Italy Drug Forecast and Market Analysis to 2022

Reportstack has announced a new market report on Hepatitis C Virus - Italy Drug Forecast and Market Analysis to 2022. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV) that results in acute or chronic presentation. The disease is often asymptomatic, but infected patients may experience fatigue, joint pain, itchy skin or jaundice. There is no effective vaccine against HCV, so the market is driven by therapeutics. Currently, drug combinations containing pegylated interferon (e.g., Roche’s Pegasys and Merck’s PegIntron) and ribavirin (e.g., Roche’s Copegus and Merck’s Rebetol) are used to treat HCV infection. Patients infected with HCV genotype 1 can also have a protease inhibitor added to their combination therapy, such as Merck’s Victrelis (boceprevir) or Vertex’s Incivek (telaprevir). The entrance of next-generation HCV therapies is expected to fundamentally change the HCV treatment algorithm. The main drivers of growth of the Italian HCV market are expected to be an increase in HCV awareness and the launch of next-generation HCV therapies. 

The current market leader in Italy is Roche’s Pegasys (peginterferon alfa-2a). The current standard of HCV therapy in Italy is a combination of interferon and ribavirin. The less-frequent dosing of peginterferon compared with standard interferon (i.e., once a week compared with three times a week) enabled peginterferon to quickly capture market share. In addition to standard interferon, Pegasys directly competes for market share with Merck’s ViraferonPeg (peginterferon alfa-2b). 

Scope
Overview of the HCV including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
Sales forecast for the top drugs in Italy from 2012-2022.
Analysis of the impact of key events as well the drivers and restraints affecting Italy HCV market.

Reasons To Buy
Understand and capitalize by identifying products that are most likely to ensure a robust return
Stay ahead of the competition by understanding the changing competitive landscape for HCV
Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
Make more informed business decisions from insightful and in-depth analysis of drug performance
Obtain sales forecast for drugs from 2012-2022 in Italy


To view the table of contents and know more details please visit Hepatitis C Virus - Italy Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

A dip in sales caused by Actos patent expiry in 2012 and three insulin products’ patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta’s patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining, with Victoza and Bydureon overtaking its shares.

Scope

- Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the UK including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the UK from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the UK type 2 diabetes market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the UK


To view the table of contents and know more details please visit PharmaPoint: Type 2 Diabetes - UK Drug Forecast and Market Analysis to 2022 report.

Similar Reports:

PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022. The type 2 diabetes market is mature and crowded with inexpensive generics. Despite being marked by a late-stage pipeline filled with me-too drugs, this market will undergo substantial growth between 2012 and 2022, more than doubling over this period. The main drivers of growth will be the dramatic increase in disease prevalence and physicians’ efforts to delay disease progression and reduce the costly burden of diabetic complications through the use of combination therapies and novel branded drugs. In the emerging markets in particular, uptake of branded drugs will increase due to rapid economic growth. We anticipate that the type 2 diabetes market will not experience a fundamental shift in the classes of drugs that are preferred by physicians. Rapid uptake of drugs from the novel class of SGLT-2 inhibitors will occur; however, DPP-4 inhibitors and GLP-1 receptor agonists will continue dominating the noninsulin type 2 diabetes space. GLP-1 receptor agonists will experience the fastest growth of all classes (CAGR of 17%), due to their weight-loss effects and their novel once-weekly administration, which is preferable to the standard once- or twice-daily therapies.

A dip in sales caused by Actos patent expiry in 2012 and three insulin products’ patent expiry by 2015 will be offset by 16 pipeline product launches over the forecast period. Byetta’s patent expiration in 2016 will not have a major impact on the market as its sales have been constantly declining with Victoza and Bydureon overtaking its shares.

Scope

- Overview of type 2 diabetes including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in the US including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in the US from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting the US type 2 diabetes market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for type 2 diabetes
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in the US


To view the table of contents and know more details please visit PharmaPoint: Type 2 Diabetes - US Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

This highly competitive market comprises over 18 different drugs, many of which already exist as generics. Atripla was the first single-tablet regimen (STR) to enter Spain in 2007, ushering in an era of STR development and commercialization. ViiV Healthcare and Gilead Sciences are the main companies pursuing STRs in order to position themselves as the market leaders in Spain.

Scope

- Overview of Spain including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Spain from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Spain HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Spain


To view the table of contents and know more details please visit PharmaPoint: HIV - Spain Drug Forecast and Market Analysis to 2022 report.

Similar Reports:

PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022. Human Immunodeficiency Virus (HIV), the causative agent of AIDS, has claimed millions of lives since its emergence. However, the advent of antiretroviral therapy (ART) has transformed the face of HIV/AIDS from a deadly disease to a manageable chronic condition for most infected individuals. Antiretroviral treatment not only reduces the viral load and reconstitutes immune function, but also decreases infection incidence rates by limiting viral transmission. The treatment algorithm in HIV has characteristically involved multiple drug regimens designed to tackle the virus on different levels. In the recent past, simplified dosing regimens through the emergence of single tablet regimens (STRs) or fixed dose combination (FDC) therapies have become increasingly popular amongst physicians and patients alike by increasing clinical efficacy thresholds and enabling patient compliance.

Atripla was the first STR to enter Italy in 2008, and STRs have been the focus of R&D ever since. ViiV Healthcare and Gilead Sciences are the main companies pursuing STRs in order to position themselves as the market leaders in Italy.

Scope

- Overview of Italy including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape.
- Detailed information on the key drugs in Italy including product description, safety and efficacy profiles as well as a SWOT analysis.
- Sales forecast for the top drugs in Italy from 2012-2022.
- Analysis of the impact of key events as well the drivers and restraints affecting Italy HIV market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return
- Stay ahead of the competition by understanding the changing competitive landscape for HIV
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential
- Make more informed business decisions from insightful and in-depth analysis of drug performance
- Obtain sales forecast for drugs from 2012-2022 in Italy


To view the table of contents and know more details please visit PharmaPoint: HIV - Italy Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in Spain is projected to grow substantially during the forecast period. During the forecast period, the primary growth drivers of the DES market in Spain will be the launch of the EU’s first prescription product for DES, as well as a rapidly increasing population of DES patients.

Scope

- Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. _x000D_
- Detailed information on the key drugs in Spain including product description, safety and efficacy profiles as well as a SWOT analysis. _x000D_
- Sales forecast for the top drugs in Spain from 2012-2022. _x000D_
- Analysis of the impact of key events as well the drivers and restraints affecting Spain DES market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return _x000D_
- Stay ahead of the competition by understanding the changing competitive landscape for DES _x000D_
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential _x000D_
- Make more informed business decisions from insightful and in-depth analysis of drug performance _x000D_
- Obtain sales forecast for drugs from 2012-2022 in Spain.


To view the table of contents and know more details please visit PharmaPoint: Dry Eye Syndrome - Spain Drug Forecast and Market Analysis to 2022 report. 

Similar Reports:

PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022


Reportstack has announced a new market report on PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022. Dry eye syndrome (DES), or keratoconjunctivitis sicca, is a multifactorial disease of the eye caused by dryness, decreased tear production, or increased tear film evaporation. DES, which is often referred to simply as dry eye, is the most prevalent form of ocular discomfort and irritation. The most common symptoms of DES are ocular irritation and discomfort, foreign body sensation, fatigue, and visual disturbances, which interfere with daily activities. In the elderly population, it is the most common reason for seeking eye care, and this is expected to increase exponentially with an aging demographic.

The DES market in China is projected to grow substantially during the forecast period. During the forecast period, the primary growth driver in this market will be the launch of Diquas and CF101 and generally increased access to medical care for China’s enormous population.

Scope

- Overview of the DES including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. 
- Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. 
- Sales forecast for the top drugs in China from 2012-2022. 
- Analysis of the impact of key events as well the drivers and restraints affecting China DES market.

Reasons to buy

- Understand and capitalize by identifying products that are most likely to ensure a robust return 
- Stay ahead of the competition by understanding the changing competitive landscape for DES 
- Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential 
- Make more informed business decisions from insightful and in-depth analysis of drug performance 
- Obtain sales forecast for drugs from 2012-2022 in China.


To view the table of contents and know more details please visit PharmaPoint: Dry Eye Syndrome - China Drug Forecast and Market Analysis to 2022 report. 

Similar Reports: